Domov › Množni mielom › Illinois
Klinične študije za Množni mielom v Illinois
31 študij za Množni mielom išče udeležence na lokacijah v Illinois.
Mesta v Illinois
- Chicago22 študij
- Cicero6 študij
- Waukegan4 študij
- Springfield4 študij
- Evanston4 študij
- Bloomington3 študij
- North Peoria3 študij
- Decatur3 študij
- Peoria3 študij
- Galesburg3 študij
- Aurora3 študij
Uradno besedilo študije (angleško)
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- in še 13
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06948084A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- University of Chicago Medical Center /ID# 278863, Chicago
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Chicago
- Research Site, Park Ridge
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Chicago Medical Center, Chicago
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT04973605A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Rush University System for Health, Chicago
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07518186A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- City of Hope Chicago, Zion
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07258511A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- University Of Illinois Medical Center, Chicago
- Loyola University Medical Center, Maywood
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Northwestern University, Chicago
- University of Chicago, Chicago
Vključevanje udeležencevFaza 4
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05201781Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT05789303TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America-Chicago, Chicago
Vključevanje udeležencevFaza 2
Starost 12 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT02693535Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06297226Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
- University of Illinois at Chicago, Chicago
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 28. avg. 2026 · NCT05344833MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Endeavor Health - Swedish Hospital, Chicago
- Endeavor Health - Evanston Hospital, Evanston
- Endeavor Health - Glenbrook Hospital Ambulatory Care Center, Glenview
- in še 6
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 24. avg. 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- in še 40
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT04566328AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Chicago
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Chicago
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 14. avg. 2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Loyola University Medical Center, Maywood
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 12. avg. 2026 · NCT07280013Mosaic Trial for Stem Cell Transplant Recipients
- Northwestern University Feinberg School of Medicine, Chicago
Vključevanje udeležencev
Starost 18 in več · Vsi spoli · Posodobljeno 3. avg. 2026 · NCT06960993Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
- Loyola University Chicago, Maywood
Vključevanje udeležencev
Starost 18 in več · Vsi spoli · Posodobljeno 22. jul. 2026 · NCT07236502A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Hope And Healing Cancer Services /ID# 268536, Hinsdale
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 13. jul. 2026 · NCT05650632Integrated Cancer Repository for Cancer Research
- Rush-Copley Cancer Care Center, Aurora
- Rush-Copley Healthcare Center, Yorkville
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 19–110 · Vsi spoli · Posodobljeno 29. jun. 2026 · NCT02012699Personalized Autologous Transplant for Multiple Myeloma
- University Illinois Chicago, Chicago
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 15. jun. 2026 · NCT04483206Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Anthony's Health, Alton
- Rush - Copley Medical Center, Aurora
- Saint Joseph Medical Center, Bloomington
- in še 41
Vključevanje udeležencevFaza 3
Vse starosti · Vsi spoli · Posodobljeno 10. jun. 2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- University of Chicago, Chicago
- University of Illinois Medical Center at Chicago, Chicago
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 4. jun. 2026 · NCT05243797Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
Vključevanje udeležencevFaza 1
Starost 13 in več · Vsi spoli · Posodobljeno 5. maj 2026 · NCT04771572Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
- University of Chicago Medical Center, Chicago
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 1. apr. 2026 · NCT05862012Hypofractionation (Radiation) Trial for Multiple Myeloma
- The University of Chicago Comprehensive Cancer Center, Chicago
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 30. mar. 2026 · NCT06270888A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Northwestern, Chicago
Vključevanje udeležencevFaza 1/2
Starost 12 in več · Vsi spoli · Posodobljeno 24. mar. 2026 · NCT04988555Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Northshore University Health System, Evanston
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 23. feb. 2026 · NCT05974150A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
- City of Hope at Chicago, Zion
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 18 in več · Vsi spoli · Posodobljeno 20. feb. 2026 · NCT07225738Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
- University of Illinois Cancer Center, Chicago
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 18. dec. 2025 · NCT05192122Vir: ClinicalTrials.gov, podatki pridobljeni 4. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.